News

Physical Activity Reduces Colorectal Cancer Morbidity and Mortality

View on the News

New Data is 'Intriguing'

Retrospective and self-reported data have many limitations, but this overview of evidence that physical activity can reduce morbidity and mortality from colorectal cancer is intriguing. The presumed potential mechanism is reducing obesity and the incidence of insulin resistance. Previously, Dr. Meyerhardt has shown that people with diabetes have increased risk of mortality from colorectal cancer. Exercise can modulate insulin metabolism and reduce insulin resistance.

One can speculate what influence this kind of data will have on the analysis of clinical trials and how clinical trials should be designed in the future. We use measures such as kidney function and liver function to stratify patients. Maybe there has to be stratification for body mass index and other measures, such as insulin resistance, in the future.

Stuart M. Lichtman, M.D., FACP, 65+ Clinical Geriatrics Program, attending physician and member, Memorial Sloan-Kettering Cancer Center, professor of medicine, Cornell University, New York.


 

FROM AN INTERNATIONAL CONFERENCE SPONSORED BY THE SOCIETY FOR INTEGRATIVE ONCOLOGY

NEW YORK – Moderate exercise can confer a measurable survival advantage in patients who have undergone treatment for colorectal cancer, said Dr. Jeffrey Meyerhardt at an international conference sponsored by the Society for Integrative Oncology.

"Published data are showing a major decrease in morbidity and mortality in patients who exercise. These are changes in actual cancer outcomes, not just quality of life measures," said Dr. Meyerhardt of the department of medical oncology, Dana-Farber Cancer Institute, Boston.

"My research really came out of patients’ questions. They wanted to know, ‘What should I be eating? Should I exercise? What else can I do to improve my chances?’ We wanted to help them live longer and live better."

Emerging data indicate that physical activity, avoidance of the typical meat-heavy Western diet patterns, maintenance of body mass index under 35 kg/m2, higher levels of vitamin D, and regular use of aspirin or other anti-inflammatory compounds reduces the risk of recurrence in colorectal cancer (CRC), Dr. Meyerhardt said during his keynote presentation.

An Australian cohort study of 526 colorectal cancer patients showed that the probability of surviving for 10 years post-diagnosis was 73% for the patients who exercised regularly prior to the cancer diagnosis, versus 54% among those who did not exercise (Gut 2006;55:62-7). The investigators noted that percent of body fat and the waist circumference were both inversely correlated with survival.

Dr. Meyerhardt and his group published an analysis of data from a National Cancer Institute–sponsored study called CALGB 89803 that involved 1,264 patients with stage II colon cancer, randomized to treatment with 5-fluorouracil and leucovorin with or without irinotecan following surgical resection.

The study was designed to assess the impact of the drug regimens on overall and disease-free survival, and found no significant differences between the two (J. Clin. Oncol. 2007;25:3456-61). However, there were substantial survival differences based on level of post-diagnosis physical activity, said Dr. Meyerhardt.

He and his colleagues stratified the study participants according to their self-reported activity levels, using the "met-hour" (metabolic equivalent task hour) as a unit of measure. For example, sitting still was defined as 1 met and slow walking was defined as 3 mets. Other activities were assigned met values according to their strenuousness. Met-hours represent the aggregate amount of time per week that a subject spent in metabolically significant activity.

The hazard ratio of recurrence or death was reduced by 49% among people who regularly had between 18 and 26 met-hours of activity per week, compared to those who had fewer than 3 met-hours per week (J. Clin. Oncol. 2006;24:3535-41). Dr. Meyerhardt said that an hour-long walk at a brisk pace of 3-4 miles per hour, three to four times per week, would put someone in the risk-reducing range.

He acknowledged that this analysis has limits in that it was based on self-reporting. Also, people who are able to exercise for 18 or more hours per week after chemotherapy and surgery for colorectal cancer are highly functioning, with good overall health status, which in and of itself would confer a survival advantage.

Data from other studies have also shown that higher activity levels predict better outcomes following colorectal cancer diagnosis. For example, the Nurses’ Health Study showed that post-diagnosis activity levels are predictive of survival. Among the women who had more than 18 met-hours of activity per week, roughly 90% were still alive 10 years after diagnosis, versus 67% of those who had less than 3 met hours per week, and 75% of those who got between 3 and 18 met-hours/week (J. Clin. Oncol. 2006;24:3527-34). In this data set, the prediagnosis activity levels were not predictive of survival, after researchers adjusted for other health status variables.

"It is not simply a matter of more active people getting less aggressive forms of cancer," said Dr. Meyerhardt. "There are statistically significant improvements in survival and reduced morbidity in patients with increased activity post-diagnosis and post-treatment."

The NHS data indicate that women who increased their activity levels post-diagnosis had about 50% reductions in hazard ratios for CRC-specific mortality and overall mortality, while those who decreased their physical activity had increases in their hazard ratios.

A soon-to-be published analysis of data from the Health Professionals Follow-Up Study, involving 51,500 male health care practitioners, showed a similar pattern of reduced overall and CRC-associated mortality among the men with the highest levels of post-diagnosis physical activity, said Dr. Meyerhardt.

He noted that these studies are observational, and a prospective study is needed to confirm their findings. The Colon Health and Life-Long Exercise Change (CHALLENGE) trial is such a study that is expected to be published in several years. An Australian-Canadian collaborative effort, this controlled study will look at the impact of direct, guided exercise training interventions on clinical outcomes in patients with high-risk stage II and III CRC following surgery and adjuvant chemotherapy.

Pages

Recommended Reading

RADIANT Trials Show Benefit of Everolimus in Neuroendocrine Tumors
MDedge Internal Medicine
Axillary Lymph Node Dissection Doesn't Improve Breast Cancer Survival
MDedge Internal Medicine
Nearly 1.3 Million Cancer Deaths Predicted for Europe in 2011
MDedge Internal Medicine
Serial Screening Program Detects Nodular Melanomas
MDedge Internal Medicine
ASCO: Discuss Palliative Care, Symptom Relief With Cancer Patients Early
MDedge Internal Medicine
New-Onset Diabetes May Help Guide Pancreatic Cancer Screening
MDedge Internal Medicine
FDA: Oncology Drug Makers Should Resist Single-Arm Trials
MDedge Internal Medicine
Sunitinib Improves Survival in Advanced Pancreatic Neuroendocrine Tumors
MDedge Internal Medicine
New Classification of Lung Adenocarcinoma Calls for EGFR Testing
MDedge Internal Medicine
FOLFOX4 Prolongs Survival in Advanced HCC
MDedge Internal Medicine